يعرض 1 - 20 نتائج من 31 نتيجة بحث عن '"Neubildung"', وقت الاستعلام: 0.50s تنقيح النتائج
  1. 1
    Academic Journal

    المصدر: Probleme de filologie: aspecte teoretice şi practice (Ediţia 7)

    مصطلحات موضوعية: Pandemie, Neologismus, Neubildung, Kompositum, Kontamination, Kofferwort

    وصف الملف: application/pdf

  2. 2
  3. 3
  4. 4
  5. 5
    Academic Journal

    المصدر: GMS German Medical Science; VOL: 9; DOC04 /20110223/

    Relation: Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999;17(1):158-67.; Ballo MT, Zagars GK, Pollack A. Radiation therapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys. 1998;42(5):1007-14. DOI:10.1016/S0360-3016(98)00285-5; Bonvalot S, Rimareix F, Paumier A, Roberti E, Bouzaiene H, Le Péchoux C. Actualisation de la strategie therapeutique locoregionale dans les sarcomes des tissus mous et les tumeurs desmoides des membres [What is new in the local approach of limb sarcomas and desmoid tumours?]. Cancer Radiother. 2010;14(6-7):455-9. DOI:10.1016/j.canrad.2010.06.016; Ferenc T, Sygut J, Kopczynski J, Mayer M, Latos-Bielenska A, Dziki A, Kulig A. Aggressive fibromatosis (desmoid tumors): definition, occurrence, pathology, diagnostic problems, clinical behavior, genetic background. Pol J Pathol. 2006;57(1):5-15.; Gluck I, Griffith KA, Biermann JS, Feng FY, Lucas DR, Ben-Josef E. Role of Radiotherapy in the Management of Desmoid Tumors. Int J Radiat Oncol Biol Phys. 2010 Jul 7. DOI:10.1016/j.ijrobp.2010.02.053; Goy BW, Lee SP, Eilber F, Dorey F, Eckardt J, Fu YS, Juillard GJ, Selch MT. The role of adjuvant radiotherapy in the treatment of resectable desmoid tumors. Int J Radiat Oncol Biol Phys. 1997;39(3):659-65. DOI:10.1016/S0360-3016(97)00334-9; Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2008;71(2):441-7. DOI:10.1016/j.ijrobp.2007.10.013; Janinis J, Patriki M, Vini L, Aravantinos G, Whelan JS. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol. 2003;14(2):181-90. DOI:10.1093/annonc/mdg064; Kumar V, Khanna S, Khanna AK, Khanna R. Desmoid tumors: experience of 32 cases and review of the literature. Indian J Cancer. 2009;46(1):34-9. DOI:10.4103/0019-509X.48593; Micke O, Seegenschmiedt MH; German Cooperative Group on Radiotherapy for Benign Diseases. Radiation therapy for aggressive fibromatosis (desmoid tumors): results of a national Patterns of Care Study. Int J Radiat Oncol Biol Phys. 2005;61(3):882-91. DOI:10.1016/j.ijrobp.2004.07.705; Nuyttens JJ, Rust PF, Thomas CR Jr, Turrisi AT 3rd. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: A comparative review of 22 articles. Cancer. 2000;88(7):1517-23. DOI:10.1002/(SICI)1097-0142(20000401)88:73.0.CO;2-9; Posner MC, Shiu MH, Newsome JL, Hajdu SI, Gaynor JJ, Brennan MF. The desmoid tumor. Not a benign disease. Arch Surg. 1989;124(2):191-6.; Pötter R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M, Dimopoulos J, Dumas I, Erickson B, Lang S, Nulens A, Petrow P, Rownd J, Kirisits C; GEC ESTRO Working Group. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol. 2006;78(1):67-77. DOI:10.1016/j.radonc.2005.11.014; Roeder F, Timke C, Oertel S, Hensley FW, Bischof M, Muenter MW, Weitz J, Buchler MW, Lehner B, Debus J, Krempien R. Intraoperative electron radiotherapy for the management of aggressive fibromatosis. Int J Radiat Oncol Biol Phys. 2010;76(4):1154-60. DOI:10.1016/j.ijrobp.2009.03.067; http://dx.doi.org/10.3205/000127; http://nbn-resolving.de/urn:nbn:de:0183-0001277; http://www.egms.de/en/journals/gms/2011-9/000127.shtml

  6. 6
    Academic Journal

    المصدر: GMS German Medical Science; VOL: 9; DOC11 /20110502/

    Relation: Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O'Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F; International Primary CNS Lymphoma Collaborative Group. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034-43. DOI:10.1200/JCO.2005.13.524; Arkenau HT, Chong G, Cunningham D, Watkins D, Agarwal R, Sirohi B, Trumper M, Norman A, Wotherspoon A, Horwich A. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol. 2007;18(3):541-5. DOI:10.1093/annonc/mdl434; Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. J Clin Oncol. 2009;27(1):114-9. DOI:10.1200/JCO.2008.16.8021; Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18(1):149-57. DOI:10.1093/annonc/mdl327; Bollen EL, Brouwer RE, Hamers S, Hermans J, Kluin M, Sankatsing SU, A-Tjak RV, Charvat MV, Kluin-Nelemans JC. Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. Arch Neurol. 1997;54(7):854-9.; Doolittle ND, Abrey LE, Shenkier TN, Tali S, Bromberg JE, Neuwelt EA, Soussain C, Jahnke K, Johnston P, Illerhaus G, Schiff D, Batchelor T, Montoto S, Kraemer DF, Zucca E. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood. 2008;111(3):1085-93. DOI:10.1182/blood-2007-07-101402; Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, Bordessoule D, Recher C, Blanc M, Molina T, Lederlin P, Coiffier B. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol. 2004;15(1):129-33. DOI:10.1093/annonc/mdh013; Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, Rose C, Tilly H, Sonet A, Lederlin P, Attal M, Brière J, Reyes F. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol. 2000;11(6):685-90. DOI:10.1023/A:1008394827806; Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol. 2002;13(7):1099-107. DOI:10.1093/annonc/mdf175; Jahnke K, Thiel E, Martus P, Schwartz S, Korfel A. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol. 2006;85(1):45-50. DOI:10.1007/s00277-005-1096-3; Keldsen N, Michalski W, Bentzen SM, Hansen KB, Thorling K. Risk factors for central nervous system involvement in non-Hodgkins-lymphoma--a multivariate analysis. Acta Oncol. 1996;35(6):703-8. DOI:10.3109/02841869609084002; Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-80.; Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Deckert M, Fimmers R, Helmstaedter C, Atasoy A, Klockgether T, Schlegel U. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21(24):4489-95. DOI:10.1200/JCO.2003.04.056; Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molina TJ, Gisselbrecht C, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102(13):4284-9. DOI:10.1182/blood-2003-02-0542; Van Besien K, Forman A, Champlin R. Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy. Ann Oncol. 1997;8(6):515-24. DOI:10.1023/A:1008248315859; Van Besien K, Gisselbrecht C, Pfreundschuh M, Zucca E. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. Leuk Lymphoma. 2008;49 Suppl 1:52-8. DOI:10.1080/10428190802311458; World Health Organization. WHO Handbook for Reporting results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979. p. 14-21. (WHO offset publication; no. 48). Available from: http://whqlibdoc.who.int/offset/WHO_OFFSET_48.pdf; http://dx.doi.org/10.3205/000134; http://nbn-resolving.de/urn:nbn:de:0183-0001348; http://www.egms.de/en/journals/gms/2011-9/000134.shtml

  7. 7
    Dissertation/ Thesis
  8. 8
  9. 9
    Dissertation/ Thesis
  10. 10
    Dissertation/ Thesis
  11. 11
    Academic Journal

    المساهمون: The Pennsylvania State University CiteSeerX Archives

    المصدر: ftp://ftp.ncbi.nlm.nih.gov/pub/pmc/bf/bf/Ger_Med_Sci_2011_Feb_23_9_Doc04.tar.gz

    وصف الملف: application/zip

  12. 12
  13. 13
  14. 14
    Dissertation/ Thesis
  15. 15
  16. 16
    Dissertation/ Thesis
  17. 17
    Electronic Resource
  18. 18
    Electronic Resource
  19. 19
    Electronic Resource

    Additional Titles: Ein seltener Desmoidtumor der Schulter - Exzision, Implantation von Brachytherapie-Applikatoren und Defektdeckung mit gestielter Muskulus Latissimus Dorsi Lappenplastik

    المصدر: GMS German Medical Science; VOL: 9; DOC04 /20110223/

    URL: http://nbn-resolving.de/urn:nbn:de:0183-0001277
    http://www.egms.de/en/journals/gms/2011-9/000127.shtml
    Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999;17(1):158-67.
    Ballo MT, Zagars GK, Pollack A. Radiation therapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys. 1998;42(5):1007-14. DOI: 10.1016/S0360-3016(98)00285-5
    Bonvalot S, Rimareix F, Paumier A, Roberti E, Bouzaiene H, Le Péchoux C. Actualisation de la strategie therapeutique locoregionale dans les sarcomes des tissus mous et les tumeurs desmoides des membres [What is new in the local approach of limb sarcomas and desmoid tumours?]. Cancer Radiother. 2010;14(6-7):455-9. DOI: 10.1016/j.canrad.2010.06.016
    Ferenc T, Sygut J, Kopczynski J, Mayer M, Latos-Bielenska A, Dziki A, Kulig A. Aggressive fibromatosis (desmoid tumors): definition, occurrence, pathology, diagnostic problems, clinical behavior, genetic background. Pol J Pathol. 2006;57(1):5-15.
    Gluck I, Griffith KA, Biermann JS, Feng FY, Lucas DR, Ben-Josef E. Role of Radiotherapy in the Management of Desmoid Tumors. Int J Radiat Oncol Biol Phys. 2010 Jul 7. DOI: 10.1016/j.ijrobp.2010.02.053
    Goy BW, Lee SP, Eilber F, Dorey F, Eckardt J, Fu YS, Juillard GJ, Selch MT. The role of adjuvant radiotherapy in the treatment of resectable desmoid tumors. Int J Radiat Oncol Biol Phys. 1997;39(3):659-65. DOI: 10.1016/S0360-3016(97)00334-9
    Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2008;71(2):441-7. DOI: 10.1016/j.ijrobp.2007.10.013
    Janinis J, Patriki M, Vini L, Aravantinos G, Whelan JS. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol. 2003;14(2):181-90. DOI: 10.1093/annonc/mdg064
    Kumar V, Khanna S, Khanna AK, Khanna R. Desmoid tumors: experience of 32 cases and review of the literature. Indian J Cancer. 2009;46(1):34-9. DOI: 10.4103/0019-509X.48593
    Micke O, Seegenschmiedt MH; German Cooperative Group on Radiotherapy for Benign Diseases. Radiation therapy for aggressive fibromatosis (desmoid tumors): results of a national Patterns of Care Study. Int J Radiat Oncol Biol Phys. 2005;61(3):882-91. DOI: 10.1016/j.ijrobp.2004.07.705
    Nuyttens JJ, Rust PF, Thomas CR Jr, Turrisi AT 3rd. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: A comparative review of 22 articles. Cancer. 2000;88(7):1517-23. DOI: 10.1002/(SICI)1097-0142(20000401)88:7<1517::AID-CNCR3>3.0.CO;2-9
    Posner MC, Shiu MH, Newsome JL, Hajdu SI, Gaynor JJ, Brennan MF. The desmoid tumor. Not a benign disease. Arch Surg. 1989;124(2):191-6.
    Pötter R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M, Dimopoulos J, Dumas I, Erickson B, Lang S, Nulens A, Petrow P, Rownd J, Kirisits C; GEC ESTRO Working Group. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol. 2006;78(1):67-77. DOI: 10.1016/j.radonc.2005.11.014
    Roeder F, Timke C, Oertel S, Hensley FW, Bischof M, Muenter MW, Weitz J, Buchler MW, Lehner B, Debus J, Krempien R. Intraoperative electron radiotherapy for the management of aggressive fibromatosis. Int J Radiat Oncol Biol Phys. 2010;76(4):1154-60. DOI: 10.1016/j.ijrobp.2009.03.067

  20. 20
    Electronic Resource

    Additional Titles: Isoliertes Zentralnervensystem-Rezidiv eines systemischen Lymphoms: Klinische Merkmale und Verlauf einer retrospektiven Analyse

    المصدر: GMS German Medical Science; VOL: 9; DOC11 /20110502/

    URL: http://nbn-resolving.de/urn:nbn:de:0183-0001348
    http://www.egms.de/en/journals/gms/2011-9/000134.shtml
    Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O'Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F; International Primary CNS Lymphoma Collaborative Group. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034-43. DOI: 10.1200/JCO.2005.13.524
    Arkenau HT, Chong G, Cunningham D, Watkins D, Agarwal R, Sirohi B, Trumper M, Norman A, Wotherspoon A, Horwich A. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol. 2007;18(3):541-5. DOI: 10.1093/annonc/mdl434
    Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. J Clin Oncol. 2009;27(1):114-9. DOI: 10.1200/JCO.2008.16.8021
    Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18(1):149-57. DOI: 10.1093/annonc/mdl327
    Bollen EL, Brouwer RE, Hamers S, Hermans J, Kluin M, Sankatsing SU, A-Tjak RV, Charvat MV, Kluin-Nelemans JC. Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. Arch Neurol. 1997;54(7):854-9.
    Doolittle ND, Abrey LE, Shenkier TN, Tali S, Bromberg JE, Neuwelt EA, Soussain C, Jahnke K, Johnston P, Illerhaus G, Schiff D, Batchelor T, Montoto S, Kraemer DF, Zucca E. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood. 2008;111(3):1085-93. DOI: 10.1182/blood-2007-07-101402
    Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, Bordessoule D, Recher C, Blanc M, Molina T, Lederlin P, Coiffier B. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol. 2004;15(1):129-33. DOI: 10.1093/annonc/mdh013
    Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, Rose C, Tilly H, Sonet A, Lederlin P, Attal M, Brière J, Reyes F. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol. 2000;11(6):685-90. DOI: 10.1023/A:1008394827806
    Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol. 2002;13(7):1099-107. DOI: 10.1093/annonc/mdf175
    Jahnke K, Thiel E, Martus P, Schwartz S, Korfel A. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol. 2006;85(1):45-50. DOI: 10.1007/s00277-005-1096-3
    Keldsen N, Michalski W, Bentzen SM, Hansen KB, Thorling K. Risk factors for central nervous system involvement in non-Hodgkins-lymphoma--a multivariate analysis. Acta Oncol. 1996;35(6):703-8. DOI: 10.3109/02841869609084002
    Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-80.
    Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Deckert M, Fimmers R, Helmstaedter C, Atasoy A, Klockgether T, Schlegel U. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21(24):4489-95. DOI: 10.1200/JCO.2003.04.056
    Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molina TJ, Gisselbrecht C, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102(13):4284-9. DOI: 10.1182/blood-2003-02-0542
    Van Besien K, Forman A, Champlin R. Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy. Ann Oncol. 1997;8(6):515-24. DOI: 10.1023/A:1008248315859
    Van Besien K, Gisselbrecht C, Pfreundschuh M, Zucca E. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. Leuk Lymphoma. 2008;49 Suppl 1:52-8. DOI: 10.1080/10428190802311458
    World Health Organization. WHO Handbook for Reporting results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979. p. 14-21. (WHO offset publication; no. 48). Available from: http://whqlibdoc.who.int/offset/WHO_OFFSET_48.pdf